TickerTalks
Browse all tickers →
TickerTalks›$BNTX
BNBNTX

BioNTech SE

Hot onWhy it's trendingX chatter spiked vs its recent normMoving on elevated volumeStrong bullish X conversation
$BNTX·$24B·Biotechnology·Healthcare
$116.57+5.1%YTD-5.3%1Y+5.2%
Mentions · last 7 days
2026-08-16: 2 posts2026-08-17: 11 posts2026-08-18: 3 posts2026-08-19: 141 posts2026-08-20: 82 posts2026-08-21: 43 posts2026-08-22: 84 posts366+17%
Price updated 3d ago·X counts updated 2d ago
BNBNTX
$BNTXBioNTech SE
$116.57+5.12%366 posts+17%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BNTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-08-23

The move is getting stronger, with heavier trading behind it.

MRK/MRNA cancer-vaccine spillover ripped it 22% in a day — the fundamentals still need the pipeline to land.

BioNTech is the German mRNA-technology pioneer that partnered with Pfizer on the COVID vaccine and has been trying to reroute the platform into cancer treatments as COVID demand fades. The recent Merck-Moderna Phase 3 cancer-vaccine catalyst produced a sympathy rally, and the question is whether BNTX has a similar readout coming.

  • The rally is externally driven: +22% single-day moves and $BNTX 120 calls printing +240% reflect the market pricing in a cancer-vaccine sympathy trade — Everest's CEO framing BNTX and MRNA as the only end-to-end mRNA biotechs with in-vivo CAR-T and cancer-vaccine capabilities is the specific bull thesis.
  • The underlying financials are in transition: Q1 revenue $120M down 34% YoY (COVID demand collapse), and the FY26 EPS estimate of -$4.49 confirms the ongoing burn while the pipeline is rebuilt — the cash cushion from the COVID cycle is what funds the pipeline for now.
  • Late-stage lung cancer data are the near-term catalyst: BioNTech's Pumitamig/Elfetabart Drozuntecan novel-novel combination WCLC 2026 data readout is what the market is waiting to see confirm the cancer-vaccine platform-value thesis.
  • The LEERINK caution is worth respecting: LEERINK explicitly said BNTX should fade because it's not in the specific MRK/MRNA readout — sympathy trades often unwind fast if the primary catalyst doesn't include the sympathy name.

A continuation of the rally requires the November 3 print to include specific pipeline data or a partnership announcement that validates the mRNA-cancer-therapeutic thesis. Invalidator: a Phase 3 readout disappointment from a competitor that dents the whole class, a specific negative pipeline update from BioNTech, or a broader risk-off in high-multiple biotech names. The prior neoantigen-vaccine failures the bears cite are a legitimate historical drag on any 'this time it's different' argument.

Agrees with X sentimentThe X view has the right skeleton — the MRK/MRNA cancer-vaccine spillover is documented, the +22% single-day move is on the tape, and the end-to-end mRNA framing is correct. The LEERINK fade note and prior neoantigen-vaccine failure reference are also valid contrarian points.

What to watch: The November 3 Q3 earnings for pipeline data and any commentary on the mRNA cancer-therapeutic strategy. Concrete pipeline progress = the rally extends; another quarter of pipeline-plans-without-data = fast unwind.

On the calendar: 2026-11-03 — Q3 earnings

sympathy rallypost covid transition

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment32 posts analyzed · as of 2026-08-22

BioNTech sentiment is bullish and euphoric after riding the MRNA cancer-vaccine breakthrough spillover. Posters flag +22% single-day moves, $BNTX 120 calls printing +240% and Everest's CEO framing BNTX and MRNA as the only end-to-end mRNA biotechs with in-vivo CAR-T and cancer-vaccine capabilities. Skeptics circulate a LEERINK note saying BNTX should fade because it is not included in the specific MRK/MRNA readout, and note prior neoantigen vaccine failures. The move-exhaustion camp is small but present.

Read the AI verdict + X sentiment for $BNTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

mRNA biotech known for Pfizer/BioNTech COVID vaccine, now advancing a broad cancer immunotherapy pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $BNTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $BNTX

Neutral — mRNA biotech known for Pfizer/BioNTech COVID vaccine, now advancing a broad cancer immunotherapy pipeline; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+52.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-15.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-52.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
77.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-3.70$-2.40-54.3%
Q1 2026May 5, 2026$-2.43$-2.54+4.4%
Q4 2025Mar 10, 2026$-1.44$-0.22-556.7%
Q3 2025Nov 3, 2025$-0.14$-1.12+87.5%
Next earningsTue, Nov 3·consensus EPS $0.86

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$120.0M-34.3%-63.2%-560%$-2.14$-485.7M
Q4 FY25$898.9M-24.5%63.3%-25.7%$-1.23$237.7M
Q3 FY25$1.5B+22.0%90.2%-3.1%$-0.12$811.1M
Q2 FY25$260.8M+102.6%70.7%-192%$-1.60$700.0M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.2B$2.1B – $2.2B-$4.49-$4.72 – -$4.2513
FY27$2.2B$1.9B – $2.6B-$4.70-$6.16 – -$3.2512
FY28$2.6B$1.4B – $3.3B-$4.41-$9.39 – -$0.6914
FY29$2.2B$1.8B – $2.7B-$4.76-$6.12 – -$3.449
FY30$2.6B$2.0B – $3.2B-$3.82-$4.91 – -$2.7613

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.83%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+25.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+19.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β1.285-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellApr 22Sierk PoettingCOO50.0K sh$5.5M
+ 5 other (5 awards) in window

See when $BNTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 263
AI summary

Iris Katharina Low-Friedrich was appointed to BioNTech SE's supervisory board effective June 26, 2026, and reports no securities beneficially owned. Routine initial Section 16 disclosure for the German mRNA vaccine company's new board member.

3New insider — initial holdingsJun 263
AI summary

Susanne Schaffert was appointed to BioNTech SE's supervisory board effective June 26, 2026, and reports no securities beneficially owned. Same routine initial Section 16 disclosure as the companion filing; two new supervisory board members were added to BioNTech on the same date.

3/ANew insider — initial holdingsApr 133/A
AI summary

Ugur Sahin, co-founder and CEO of BioNTech SE (BNTX), filed an amended Form 3/A on March 18, 2026, correcting or supplementing his initial ownership disclosure. Sahin is a major beneficial owner and the scientific and commercial leader of the mRNA vaccine company based in Mainz, Germany. The amendment updates the record of his initial holdings.

3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
+ 30 other (17 6-Ks · 8 3s · 2 20-F/As · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session247wallst.com·3d agoModerna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips247wallst.com·4d agoBioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026globenewswire.com·4d agoWhy Is BioNTech Stock Surging on Wednesday?benzinga.com·5d agoBioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.fool.com·11d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$CAPR$IOVA$NWBO$SLS$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport